Pipeline

Rain intends to build a targeted oncology platform, with the first program, tarloxotinib (Tarlox), holding promise across various indications

Tarlox Development Overview

		Discovery	Preclinical	Phase 1	Phase 2
NSCLC	HER2 Ex20Ins EGFR Ex20Ins Relapsed (Monotherapy)
Pan-Tumor	NRG / HER Fusions1 Relapsed (Monotherapy)
Pan-Tumor	HER2 Mutant Relapsed (Monotherapy)

Trial recruiting

1. Includes EGFR kinase domain duplications (KDD), EGFR fusions, ERBB2, and ERBB4 fusions